This section displays the selected news item. Show all news items.
VirionHealth Raises Series A Funding from Abingworth
VirionHealth Ltd, a new biotechnology company developing novel therapeutics for respiratory viral infections, today announced that it has raised up to £13 million in Series A funding from Abingworth, the international investment group dedicated to life sciences.
VirionHealth, founded on pioneering research by Professors Nigel Dimmock and Andrew Easton at the University of Warwick’s School of Life Sciences, is a world leader in the development of precisely engineered, non-infectious, defective interfering particles. This new class of biological antiviral acts by outcompeting replication of infectious viruses to both prevent and treat viral infections.
(Image: Laura Lane from Warwick Ventures, Professor Andrew Easton and Professor Nigel Dimmock on day of signing)